MTOR and hepatocellular carcinoma: Furthermore, problems remain due to the rapid drug resistance against AKT and mTOR inhibitor treatment in HCC cells, both in vitro and in vivo, which may be attributed to the rapid outgrowth of CSCs [61,62,63,64,65,66,67].